Literature DB >> 26692109

Stem cell transplantation in adults with acute myelogenous leukemia, normal cytogenetics, and the FLT3-ITD mutation.

Ellin Berman1, Molly Maloy2, Sean Devlin3, Suresh Jhanwar4, Esperanza Papadopoulos2, Ann Jakubowski2.   

Abstract

Following chemotherapy, patients with acute myelogenous leukemia (AML), normal cytogenetics, and the FLT3-ITD mutation have shorter survival compared to wild type (WT) patients. To determine the role of stem cell transplantation (SCT), we performed a retrospective review of adult patients with AML who underwent SCT at our center between January 1, 2007 and December 31, 2011. Of the 200 patients transplanted, 79 patients (40%) had normal cytogenetics; of these, 17 (22%) had the FLT3-ITD mutation, 35 were WT (44%), and 27 (34%) did not have FLT3 testing performed. Clinical characteristics were similar in each group. At four years, overall survival (OS) between FLT3 positive and WT groups was similar: 0.54 (95% CI 0.29-0.75) versus 0.73 (95% CI 0.53-0.99), p=0.18. Relapse rates were also similar, 0.09 (95% CI 0.02-0.21) versus 0.12 (95% CI: 0.02-0.32); p=0.67. We conclude that SCT can abrogate the poor prognosis in FLT3-ITD positive patients.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AML; FLT3-ITD; Stem cell transplant

Mesh：

Substances：

Year:  2015        PMID： 26692109      PMCID： PMC5053396          DOI： 10.1016/j.leukres.2015.11.010

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  25 in total

1.  Allogeneic hematopoietic stem cell transplant for hematological malignancies from mismatched 9/10 human leukocyte antigen unrelated donors: comparison with transplants from 10/10 unrelated donors and human leukocyte antigen identical siblings.

Authors:  Mauricette Michallet; Mohamad Sobh; Caroline Serrier; Stéphane Morisset; Hélène Labussière; Sophie Ducastelle; Fiorenza Barraco; Lila Gilis; Xavier Thomas; Franck E Nicolini
Journal:  Leuk Lymphoma       Date:  2014-08-20

2.  The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype.

Authors:  Friederike Schneider; Eva Hoster; Michael Unterhalt; Stephanie Schneider; Annika Dufour; Tobias Benthaus; Gudrun Mellert; Evelyn Zellmeier; Purvi M Kakadia; Stefan K Bohlander; Michaela Feuring-Buske; Christian Buske; Jan Braess; Achim Heinecke; Maria C Sauerland; Wolfgang E Berdel; Thomas Büchner; Bernhard J Wörmann; Wolfgang Hiddemann; Karsten Spiekermann
Journal:  Blood       Date:  2012-02-28       Impact factor: 22.113

3.  Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome.

Authors:  M J Keating; T L Smith; H Kantarjian; A Cork; R Walters; J M Trujillo; K B McCredie; E A Gehan; E J Freireich
Journal:  Leukemia       Date:  1988-07       Impact factor: 11.528

4.  A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation.

Authors:  Doris M Ponce; Craig Sauter; Sean Devlin; Marissa Lubin; Anne Marie Gonzales; Nancy A Kernan; Andromachi Scaradavou; Sergio Giralt; Jenna D Goldberg; Guenther Koehne; Miguel A Perales; James W Young; Hugo Castro-Malaspina; Ann Jakubowski; Esperanza B Papadopoulos; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2013-02-14       Impact factor: 5.742

5.  Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303.

Authors:  Steven M Devine; Shelly Carter; Robert J Soiffer; Marcelo C Pasquini; Parameswaran N Hari; Anthony Stein; Hillard M Lazarus; Charles Linker; Edward A Stadtmauer; Edwin P Alyea; Carolyn A Keever-Taylor; Richard J O'Reilly
Journal:  Biol Blood Marrow Transplant       Date:  2011-02-12       Impact factor: 5.742

6.  T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin.

Authors:  Ann A Jakubowski; Trudy N Small; James W Young; Nancy A Kernan; Hugo Castro-Malaspina; Katherine C Hsu; Miguel-Angel Perales; Nancy Collins; Christine Cisek; Michelle Chiu; Marcel R M van den Brink; Richard J O'Reilly; Esperanza B Papadopoulos
Journal:  Blood       Date:  2007-08-23       Impact factor: 22.113

7.  No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

Authors:  Rosemary E Gale; Robert Hills; Panagiotis D Kottaridis; Sivatharsini Srirangan; Keith Wheatley; Alan K Burnett; David C Linch
Journal:  Blood       Date:  2005-08-02       Impact factor: 22.113

8.  Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.

Authors:  Sabine Kayser; Richard F Schlenk; Martina Correa Londono; Frank Breitenbuecher; Kerstin Wittke; Juan Du; Silja Groner; Daniela Späth; Jürgen Krauter; Arnold Ganser; Hartmut Döhner; Thomas Fischer; Konstanze Döhner
Journal:  Blood       Date:  2009-07-14       Impact factor: 22.113

Review 9.  Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist.

Authors:  Natasha Kekre; Joseph H Antin
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

10.  Structural and numerical variation of FLT3/ITD in pediatric AML.

Authors:  Soheil Meshinchi; Derek L Stirewalt; Todd A Alonzo; Titus J Boggon; Robert B Gerbing; Jennifer L Rocnik; Beverly J Lange; D Gary Gilliland; Jerald P Radich
Journal:  Blood       Date:  2008-02-27       Impact factor: 22.113
View more
  3 in total

Review 1.  FLT3-ITD and its current role in acute myeloid leukaemia.

Authors:  Francisco Alejandro Lagunas-Rangel; Venice Chávez-Valencia
Journal:  Med Oncol       Date:  2017-05-03       Impact factor: 3.064

Review 2.  The role of FLT3 inhibitors as maintenance therapy following hematopoietic stem cell transplant.

Authors:  Grace Xiuqing Li; Lan Wang; Bassam Yaghmour; Giridharan Ramsingh; George Yaghmour
Journal:  Leuk Res Rep       Date:  2018-07-19

3.  Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Xavier Poiré; Myriam Labopin; Emmanuelle Polge; Jakob Passweg; Charles Craddock; Didier Blaise; Jan J Cornelissen; Liisa Volin; Nigel H Russell; Gérard Socié; Mauricette Michallet; Nathalie Fegueux; Patrice Chevallier; Arne Brecht; Mathilde Hunault-Berger; Mohamad Mohty; Jordi Esteve; Arnon Nagler
Journal:  Haematologica       Date:  2017-12-14       Impact factor: 9.941
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.